Betamethasone Acetate / Betamethasone Sodium Phosphate Injectable Suspension, 7 mg/ mL,10 mL Mult...
FDA Drug Recall #D-1454-2016 — Class II — August 1, 2016
Recall Summary
| Recall Number | D-1454-2016 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 1, 2016 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Isomeric Pharmacy Solution, LLC |
| Location | Salt Lake City, UT |
| Product Type | Drugs |
| Quantity | 2,331 vials |
Product Description
Betamethasone Acetate / Betamethasone Sodium Phosphate Injectable Suspension, 7 mg/ mL,10 mL Multi-Dose vial for injection, Rx Only, Isomeric Pharmacy Solution, 2401 Foothill Dr., Salt Lake City, UT 84109
Reason for Recall
Lack of processing controls: Isomeric Pharmacy Solution, LLC is recalling Betamethasone Acetate / Betamethasone Sodium Phosphate 7 mg/mL INJ SUSP because of the potential of drug clumps in the vial of the sterile drug product and larger particle sizes.
Distribution Pattern
Nationwide and Puerto Rico
Lot / Code Information
Lot# 03037, Exp 8/17/16; 03042, 03043, Exp 8/31/16; 04043, Exp 9/29/16; 04047, 04048, Exp 10/1/16; 04052, 04053, Exp10/2/16; 05042, Exp 10/29/16; 05046, Exp 11/2/16; 05048, 05049, Exp 11/3/16; 05050 Exp 11/4/16
Other Recalls from Isomeric Pharmacy Solution, LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0685-2017 | Class II | Cyanocobalamin 1 mg/mL/ Methionine 25 mg/mL/ In... | Apr 6, 2017 |
| D-0684-2017 | Class II | Triamcinolone Diacetate 40 mg/mL, 10 mL Multi-D... | Apr 6, 2017 |
| D-0686-2017 | Class II | Testosterone Cypionate 200 mg/mL, Testosterone ... | Apr 6, 2017 |
| D-0683-2017 | Class II | Triamcinolone Acetonide 40 mg/mL, Lidocaine HCl... | Apr 6, 2017 |
| D-0681-2017 | Class II | Methylprednisolone Acetate 40 mg/mL, Lidocaine ... | Apr 6, 2017 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.